Drug utilisation and health outcomes of pharmacotherapy
We are a transversal group, we have a wide knowledge and training in relation to pharmacotherapy with a high complexity and specialization. We are experts in the safe and effective use of medicines, applying efficiency and innovation criteria. On the other hand, being a central service, we have experience in process management.
Our clinical areas with greater presence of pharmacists are: elderly patient (geriatrics), infectious (HIV, HCV, HBV, HBV, PROA), hematology, rheumatology, dermatology, neurology and emergency. We offer:
- Pharmacovigilance, medication safety experience.
- Knowledge and availability of medications.
- Data on the use and consumption of medicines.
- Preparation of drug preparations.
- Clean rooms.
- Drug-related technologies.
- Structure for the management and development of Clinical Trials.
- Quality Management System Certification.
ACTIVITY INDICATORS 2025
- 6 private projects led
- 12 clinical studies
- 20 publications
- FI: 76.20
- Q1 publications: 4 (12%)
- Publications in Q1: 2 (10%)
- 2 doctoral theses supervised and defended
- 2 awards
- Project reviewers: 7 researchers
- Editorial board members: 2 researchers
- Translation: 3 training programs, 1 teaching guide, and 7 translation documents
- 6 visiting scholars hosted for a total of 32 months: Polytechnic University of Madrid
Milestones
- Awarded a grant from the IRYCIS's Special Support Program for R&D&I Projects by ESF Staff (PASIF) to carry out the project "PCAR-T-PHAR: CAR-T-PHARmacotherapeutic follow-up. Implementation in clinical practice of a comprehensive pharmacotherapeutic follow-up program for patients undergoing cell therapy and other therapies, led by Paula Guijarro and further recognized by the award for Best Resident at Central Services 2025.
- The group secured its first Río Hortega grant, awarded to Hilario Martínez-Barros at the AES 2024 (CM24/00152) and funded by the ISCIII. This contract allows for the continuation of the project "e-REALITI: Evaluation and monitoring of real-world outcomes to optimize access to therapeutic innovation," which was launched thanks to the 6th REX-PADI Grant 2023-2024.
- Rodríguez S, Sáez de la Fuente J, Fuertes L, Escudero R, Ruiz P, Guijarro P, Gioia F, Pintor MDR, Álvarez A. Real-life experience with the use of cefiderocol in non-critically ill patients in a tertiary care hospital. Enferm Infecc Microbiol Clin (Engl Ed). 2025;43(8): 510-514. DOI:10.1016/j.eimce.2025.05.009. A retrospective observational study to evaluate the efficacy and safety of cefiderocol in real-world settings.
- Esteban B, Anaya BJ, Pérez Menéndez C, Vicente N, Serrano DR, Álvarez A, Fortún J, Martín P. Stability of Ceftobiprole Medocaril in Portable Elastomeric Infusion Devices. Infect. Dis. Ther. 2025;14(8): 1685-1696. DOI:10.1007/s40121-025-01174-7. This publication summarizes the stability of ceftobiprole in elastomeric infusion devices that patients can take with them outside the hospital, thereby improving their quality of life without compromising efficacy and safety. HPLC analysis was performed, and the drug was found to be stable for 24 hours at room temperature in saline within elastomeric infusion pumps.
- The group's participation in initiatives with high social and public outreach impact, aimed at raising awareness, prevention, and health promotion, in observance of World Dysphagia Day, World Elderly Day, and World Patient Safety Day. These actions included activities open to the public, such as roundtable discussions for patients, as well as innovative formats for scientific outreach through podcasts and webinars, contributing to the transfer of knowledge generated by the group to society.
